<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37650499</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1757-6199</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>15</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Bioanalysis</Title><ISOAbbreviation>Bioanalysis</ISOAbbreviation></Journal><ArticleTitle>Ultrasensitive digital immunoassays for SOD1 conformation in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>927</StartPage><EndPage>936</EndPage><MedlinePgn>927-936</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4155/bio-2023-0103</ELocationID><Abstract><AbstractText><b>Aim:</b> The aim of this study was to detect misfolded Cu/Zn SOD1 as a potential biomarker for amyotrophic lateral sclerosis (ALS). <b>Materials &amp; methods:</b> Two ultrasensitive immunodetection assays were developed for the quantification of total and misfolded SOD1. <b>Results:</b> The detection of total and misfolded SOD1&#xa0;was possible in human serum and cerebrospinal fluid. Total SOD1 was increased in cerebrospinal fluid from ALS patients. Misfolded SOD1 had low and variable expression in both control and ALS patient samples. <b>Conclusion:</b> These assays hold promise for improving our understanding of ALS and&#xa0;its detection, and could lead to more effective treatment options in the future. Further studies in larger cohorts are&#xa0;now required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morichon</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>LBPC-PPC, University of Montpellier, CHU Montpellier, INM INSERM, Montpellier, 34295, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirtz</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-7313-0629</Identifier><AffiliationInfo><Affiliation>LBPC-PPC, University of Montpellier, CHU Montpellier, INM INSERM, Montpellier, 34295, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiers</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>LBPC-PPC, University of Montpellier, CHU Montpellier, INM INSERM, Montpellier, 34295, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mezghrani</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INM, University of Montpellier, INSERM, Montpellier, 34295, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raoul</LastName><ForeName>C&#xe9;dric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INM, University of Montpellier, INSERM, Montpellier, 34295, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esselin</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Montpellier, CHU Montpellier, INM, INSERM, Montpellier, 34295, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Cruz</LastName><ForeName>Elisa De</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Montpellier, CHU Montpellier, INM, INSERM, Montpellier, 34295, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Julien</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuroscience, CERVO Brain Research Centre, University Laval, Quebec City, 23027, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camu</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Montpellier, CHU Montpellier, INM, INSERM, Montpellier, 34295, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6117-562X</Identifier><AffiliationInfo><Affiliation>LBPC-PPC, University of Montpellier, CHU Montpellier, INM INSERM, Montpellier, 34295, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INM, University of Montpellier, INSERM, Montpellier, 34295, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>misSOD1</GrantID><Agency>ARSLA: Association pour la recherche sur la SLA</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bioanalysis</MedlineTA><NlmUniqueID>101512484</NlmUniqueID><ISSNLinking>1757-6180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001681" MajorTopicYN="N">Biological Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008968" MajorTopicYN="N">Molecular Conformation</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease associated with protein misfolding, including Cu/Zn SOD1. In this study, we set up a method for detecting normal and pathological misfolded SOD1 in human serum and cerebrospinal fluid. SOD1 was increased in ALS and misfolded SOD1 had&#xa0;low and variable expression in both control and ALS. These assays holds promise for improving our understanding of ALS and its diagnosis.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">conformational immunoassay</Keyword><Keyword MajorTopicYN="N">serum</Keyword><Keyword MajorTopicYN="N">single molecule array</Keyword><Keyword MajorTopicYN="N">superoxide dismutase 1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37650499</ArticleId><ArticleId IdType="doi">10.4155/bio-2023-0103</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>